| Title : Potential acetylcholinesterase inhibitors to treat Alzheimer's disease - Saud_2024_Eur.Rev.Med.Pharmacol.Sci_28_2522 |
| Author(s) : Saud A , Krishnaraju V , Taha A , Kalpana K , Malarkodi V , Durgaramani S , Vinoth Prabhu V , Saleh FA , Ezhilarasan S |
| Ref : Eur Rev Med Pharmacol Sci , 28 :2522 , 2024 |
| Abstract : OBJECTIVE: Alzheimer's disease (AD) is identified by neuropathological symptoms, and there is now no effective treatment for the condition. A lack of the brain neurotransmitter acetylcholine has been related to the etiology of Alzheimer's disease. Acetylcholinesterase is an enzyme that breaks down acetylcholine to an inactive form and causes the death of cholinergic neurons. Conventional treatments were used but had less effectiveness. Therefore, there is a crucial need to identify alternative compounds with potential anti-cholinesterase agents and minimal undesirable effects. MATERIALS AND METHODS: Fluoroquinolones and benzimidazole-benzothiazole derivatives offer antimicrobial, anti-inflammatory, anti-oxidant, anti-diabetic, and anti-Alzheimer activities. To enhance the chemical portfolio of cholinesterase inhibitors, a variety of fluoroquinolones and benzimidazole-benzothiazole compounds were evaluated against acetylcholinesterase (AChE) butyrylcholinesterase (BChE) enzymes. For this purpose, molecular docking and adsorption, distribution, metabolism, excretion, and toxicology ADMET models were used for in-silico studies for both AChE and BChE enzymes to investigate possible binding mechanisms and drug-likeness of the compounds. The inhibitory effect of docked heterocyclic compounds was also verified in vitro against AChE and BChE enzymes. Fluoroquinolones (Z, Z3, Z4, Z6, Z8, Z12, Z15, and Z9) and benzimidazole-benzothiazole compounds (TBIS-16, TBAF-1 to 9) passed through the AChE inhibition assay and their IC50 values were calculated. RESULTS: The compound 1-ethyl-6-fluoro-7-(4-(2-(4-nitrophenylamino)-2-oxoethyl)piperazin-1-yl) -4-oxo-1,4 di-hydroquinoline-3-carboxylic acid and 2-((1H-benzo[d]imidazol-2-yl)methyl)-N'-(3-bromobenzyl)-4-hydroxy-2H-thiochromene-3-carbohydrazide 1,1-dioxide (Z-9 and TBAF-6) showed the lowest IC50 values against AChE/BChE (0.37+/-0.02/2.93+/-0.03 microM and 0.638+/-0.001/1.31+/-0.01 microM, respectively) than the standard drug, donepezil (3.9+/-0.01/4.9+/-0.05 microM). During the in-vivo investigation, behavioral trials were performed to analyze the neuroprotective impact of Z-9 and TBAF-6 compounds on AD mouse models. The groups treated with Z-9 and TBAF-6 compounds had better cognitive behavior than the standard drug. CONCLUSIONS: This study found that Z-9 (Fluoroquinolones) and TBAF-6 (benzimidazole-benzothiazole) compounds improve behavioral and biochemical parameters, thus treating neurodegenerative disorders effectively. |
| ESTHER : Saud_2024_Eur.Rev.Med.Pharmacol.Sci_28_2522 |
| PubMedSearch : Saud_2024_Eur.Rev.Med.Pharmacol.Sci_28_2522 |
| PubMedID: 38567612 |
Saud A, Krishnaraju V, Taha A, Kalpana K, Malarkodi V, Durgaramani S, Vinoth Prabhu V, Saleh FA, Ezhilarasan S (2024)
Potential acetylcholinesterase inhibitors to treat Alzheimer's disease
Eur Rev Med Pharmacol Sci
28 :2522
Saud A, Krishnaraju V, Taha A, Kalpana K, Malarkodi V, Durgaramani S, Vinoth Prabhu V, Saleh FA, Ezhilarasan S (2024)
Eur Rev Med Pharmacol Sci
28 :2522